Marwa S. Zaghloul

Dr. Marwa S. Zaghloul

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
MZMarwa S. Zaghloul
Marwa S. Zaghloul
MEMahmoud Elshal
Mahmoud Elshal
MAMarwa E. Abdelmageed
Marwa E. Abdelmageed

1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Marwa AbdelmageedMarwa Abdelmageed
Marwa Abdelmageed
MNManar A. Nader
Manar A. Nader
MZMarwa S. Zaghloul
Marwa S. Zaghloul

1 December 2017 in Egyptian Journal of Basic and Applied Sciences
Verified
Journal Article
Open access
MZMarwa S. Zaghloul
Marwa S. Zaghloul
RARamy Ahmed Abdel-Salam
Ramy Ahmed Abdel-Salam
ESEman Said
Eman Said
GSGhada Mohamed Suddek
Ghada Mohamed Suddek
HSHatem Abdel-Rahman Salem
Hatem Abdel-Rahman Salem
Pulmonary fibrosis is a progressive fatal lung disorder with significantly high mortality rates. Bleomycin (BLM) is one of the most commonly used chemotherapeutic agents for treatment of several carcinomas. The most severe adverse effect of BLM is pulmonary toxicity; therefore, BLM has been repeatedly reported to be considered amongst the most widely used agents for induction of experimental pulmonary fibrosis. In the current study, flavocoxid has been investigated for its ability to ameliorate BLM-induced pulmonary fibrosis. BLM was instilled intratracheally and flavocoxid was administered orally (20â¯mg/kg) for 5 weeks; one week pre- and 5 weeks post BLM instillation. Flavocoxid significantly decreased lung/body weight index, BALFâs lactate dehydrogenase activity, total protein content and total cell count, lymphocyte and neutrophil counts. Flavocoxid significantly decreased lung MDA content, increased lung GSH content, SOD activity, serum total antioxidant capacity and decreased lung NO content. Moreover, flavocoxid reduced lung content of IL-10. In addition, flavocoxid significantly ameliorated histological changes and prevented collagen deposition with paralleled decrease in lung hydroxyproline content. In conclusion; flavocoxid can be proposed to be a potential therapeutic agent for management of pulmonary fibrosis. Keywords: Bleomycin, Flavocoxid, IL-10, Collagen, Fibrosi

14 January 2020 in Pharmacological Reports
Verified
Journal Article
Closed access
PDF file
MSMarwa S. Serrya
Marwa S. Serrya
MZMarwa S. Zaghloul
Marwa S. Zaghloul

22 February 2022 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
RARehab S. Abdelrahman
Rehab S. Abdelrahman
RARamy A. Abdelsalam
Ramy A. Abdelsalam
MZMarwa S. Zaghloul
Marwa S. Zaghloul

30 September 2015 in Human & Experimental Toxicology
Verified
Journal Article
Closed access
MNMa Nader
Ma Nader
NGNm Gamiel
Nm Gamiel
HEH El-Kashef
H El-Kashef
MZMarwa S. Zaghloul
Marwa S. Zaghloul
This study was designed to investigate the effect of agmatine sulfate (AG, CAS2482-00-0) in nicotine (NIC)-induced vascular endothelial dysfunction (VED) in rabbits. NIC was administered to produce VED in rabbits with or without AG for 6 weeks. Serum lipid profile, serum thiobarbituric acid reactive substances, reduced glutathione, superoxide dismutase generation, serum nitrite/nitrate, serum vascular cellular adhesion molecule-1 (VCAM-1), and aortic nuclear factor κB (NF-κB) levels were analyzed.Treatment with AG markedly improves lipid profile and prevented NIC-induced VED and oxidative stress. The mechanism of AG in improving NIC-induced VED may be due to the significant reduction in serum VCAM-1 levels and aortic NF-κB. Thus, it may be concluded that AG reduces the oxidative stress, nitric oxide production, VCAM-1 levels, and aortic NF-κB expression, thereby consequently improving the integrity of vascular endothelium.